Loading
Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval.
Jesús Berdeja (Sarah Cannon Research Institute, Nashville) was principal investigator and first author of CARTITUDE-1, the pivotal trial showing the BCMA CAR-T ciltacabtagene autoleucel produces responses in 98% of heavily pretreated myeloma patients with median progression-free survival near three years, the deepest responses seen in relapsed myeloma. He runs a large community-based early-phase programme.
| Title | Journal | Year |
|---|---|---|
| Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study | Lancet | 2021 |
| Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 final results | JCO | 2025 |
| CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma | The Lancet | 2021 |
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tags myeloma, car-t.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tags myeloma, car-t.
Shares CARTITUDE-1, Ciltacabtagene autoleucel, BCMA, CAR-T cell therapy.
Shares CARTITUDE-1, CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma, Ciltacabtagene autoleucel, Multiple myeloma.
Shares CARTITUDE-1, Ciltacabtagene autoleucel.
Shares Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.